{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:51:27Z","timestamp":1790142687689,"version":"4.0.1"},"reference-count":169,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer remains the second leading cause of death in the US, accounting for 25% of all deaths nationwide. Immunotherapy techniques bolster the immune cells\u2019 ability to target malignant cancer cells and have brought immense improvements in the field of cancer treatments. One important inhibitory protein in T cells, programmed cell death protein 1 (PD-1), has become an invaluable target for cancer immunotherapy. While anti-PD-1 antibody therapy is extremely successful in some patients, in others it fails or even causes further complications, including cancer hyper-progression and immune-related adverse events. Along with countless translational studies of the PD-1 signaling pathway, there are currently close to 5,000 clinical trials for antibodies against PD-1 and its ligand, PD-L1, around 80% of which investigate combinations with other therapies. Nevertheless, more work is needed to better understand the PD-1 signaling pathway and to facilitate new and improved evidence-based combination strategies. In this work, we consolidate recent discoveries of PD-1 signaling mediators and their therapeutic potential in combination with anti-PD-1\/PD-L1 agents. We focus on the phosphatases SHP2 and PTPN2; the kinases ITK, VRK2, GSK-3, and CDK4\/6; and the signaling adaptor protein PAG. We discuss their biology both in cancer cells and T cells, with a focus on their role in relation to PD-1 to determine their potential in therapeutic combinations. The literature discussed here was obtained from a search of the published literature and ClinicalTrials.gov with the following key terms: checkpoint inhibition, cancer immunotherapy, PD-1, PD-L1, SHP2, PTPN2, ITK, VRK2, CDK4\/6, GSK-3, and PAG. Together, we find that all of these proteins are logical and promising targets for combination therapy, and that with a deeper mechanistic understanding they have potential to improve the response rate and decrease adverse events when thoughtfully used in combination with checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fimmu.2022.927265","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T11:18:04Z","timestamp":1657797484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Combination Approaches to Target PD-1 Signaling in Cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Emily K.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Strazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and Opportunities in the PD1\/PDL1 Inhibitor Clinical Trial Landscape","author":"Upadhaya","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-018-0770-0","article-title":"Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors","volume":"20","author":"Sandigursky","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.810472","article-title":"Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review","volume":"9","author":"Liu","year":"2022","journal-title":"Front Nutr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00204-y","article-title":"Combinations Take Centre Stage in PD1\/PDL1 Inhibitor Clinical Trials","volume":"20","author":"Upadhaya","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.1.185","article-title":"A Two-Step, Two-Signal Model for the Primary Activation of Precursor Helper T Cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0277-x","article-title":"The Yin and Yang of Co-Inhibitory Receptors: Toward Anti-Tumor Immunity Without Autoimmunity","volume":"30","author":"Schnell","year":"2020","journal-title":"Cell Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401492","article-title":"CD28 Inhibits T Cell Adhesion by Recruiting CAPRI to the Plasma Membrane","volume":"194","author":"Strazza","year":"2015","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.07.055","article-title":"The Coreceptor Programmed Death 1 Inhibits T-Cell Adhesion by Regulating Rap1","volume":"135","author":"Azoulay-Alfaguter","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 Signaling in Primary T Cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.014745","article-title":"Quantitative Phosphoproteomic Analysis Reveals Involvement of PD-1 in Multiple T Cell Functions","volume":"295","author":"Tocheva","year":"2020","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","article-title":"Interaction of SHP-2 SH2 Domains With PD-1 ITSM Induces PD-1 Dimerization and SHP-2 Activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Commun Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710437115","article-title":"Affinity Purification Mass Spectrometry Analysis of PD-1 Uncovers SAP as a New Checkpoint Inhibitor","volume":"115","author":"Peled","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202100758","article-title":"The PD-1 Interactome","volume":"5","author":"Wang","year":"2021","journal-title":"Adv Biol (Weinh)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aal2880","article-title":"The Tyrosine Phosphatase SHP-1 Promotes T Cell Adhesion by Activating the Adaptor Protein CrkII in the Immunological Synapse","volume":"10","author":"Azoulay-Alfaguter","year":"2017","journal-title":"Sci Signaling"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed Death-1 Pathway in Cancer and Autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-021-01437-8","article-title":"SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function","volume":"44","author":"Strazza","year":"2021","journal-title":"Inflammation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application","volume":"63","author":"Yuan","year":"2020","journal-title":"J Med Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23125","article-title":"Crystal Structure of Human Protein Tyrosine Phosphatase SHP-1 in the Open Conformation","volume":"112","author":"Wang","year":"2011","journal-title":"J Cell Biochem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(01)00369-0","article-title":"Site-Specific Incorporation of a Phosphotyrosine Mimetic Reveals a Role for Tyrosine Phosphorylation of SHP-2 in Cell Signaling","volume":"8","author":"Lu","year":"2001","journal-title":"Mol Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290055","article-title":"The SHP-2 Tyrosine Phosphatase: Signaling Mechanisms and Biological Functions","volume":"10","author":"Qu","year":"2000","journal-title":"Cell Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1021\/bi5002695","article-title":"Molecular Basis of Gain-Of-Function LEOPARD Syndrome-Associated SHP2 Mutations","volume":"53","author":"Yu","year":"2014","journal-title":"Biochemistry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10038-005-0239-7","article-title":"Functional Analysis of PTPN11\/SHP-2 Mutants Identified in Noonan Syndrome and Childhood Leukemia","volume":"50","author":"Niihori","year":"2005","journal-title":"J Hum Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in Cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J Cell Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 Pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 Associate With Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 Upon Primary Human T Cell Stimulation, But Only Receptor Ligation Prevents T Cell Activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1016\/j.celrep.2019.05.041","article-title":"Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy","volume":"27","author":"Celis-Gutierrez","year":"2019","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.9.1417","article-title":"The Phosphotyrosine Phosphatase SHP-2 Participates in a Multimeric Signaling Complex and Regulates T Cell Receptor (TCR) Coupling to the Ras\/mitogen-Activated Protein Kinase (MAPK) Pathway in Jurkat T Cells","volume":"187","author":"Frearson","year":"1998","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17252","DOI":"10.1038\/s41598-019-53463-0","article-title":"Phosphorylation of PD-1-Y248 Is a Marker of PD-1-Mediated Inhibitory Function in Human T Cells","volume":"9","author":"Bardhan","year":"2019","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.10.010","article-title":"The Space and Time Frames of T Cell Activation at the Immunological Synapse","volume":"584","author":"Valitutti","year":"2010","journal-title":"FEBS Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 Inhibits T-Cell Receptor Induced Phosphorylation of the ZAP70\/CD3zeta Signalosome and Downstream Signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911571","article-title":"Blocking Interaction Between SHP2 and PD-1 Denotes a Novel Opportunity for Developing PD-1 Inhibitors","volume":"12","author":"Fan","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256416","article-title":"Genomic Data From NSCLC Tumors Reveals Correlation Between SHP-2 Activity and PD-L1 Expression and Suggests Synergy in Combining SHP-2 and PD-1\/PD-L1 Inhibitors","volume":"16","author":"Toral","year":"2021","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937902","article-title":"Resistance to Immune Checkpoint Inhibitors in non-Small Cell Lung Cancer: Biomarkers and Therapeutic Strategies","volume":"12","author":"Walsh","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0744","article-title":"SHP-2 and PD-L1 Inhibition Combined With Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 Inhibition Triggers Anti-Tumor Immunity and Synergizes With PD-1 Blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"B38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","article-title":"Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo","volume":"23","author":"Rota","year":"2018","journal-title":"Cell Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(99)00019-2","article-title":"Tec Family of Protein-Tyrosine Kinases: An Overview of Their Structure and Function","volume":"10","author":"Mano","year":"1999","journal-title":"Cytokine Growth Factor Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s Tyrosine Kinase in B Cells and Malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2174\/156802609789044443","article-title":"ITK Inhibitors in Inflammation and Immune-Mediated Disorders","volume":"9","author":"Sahu","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194752","article-title":"Epstein-Barr Virus in Inborn Immunodeficiency-More Than Infection","volume":"13","author":"Lino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01958-z","article-title":"Role of the IL-2 Inducible Tyrosine Kinase ITK and its Inhibitors in Disease Pathogenesis","volume":"98","author":"Lechner","year":"2020","journal-title":"J Mol Med (Berl)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00635-7","article-title":"Inhibiting Bruton\u2019s Tyrosine Kinase in CLL and Other B-Cell Malignancies","volume":"14","author":"Lucas","year":"2019","journal-title":"Target Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668996","article-title":"Bruton\u2019s Tyrosine Kinase and Its Isoforms in Cancer","volume":"9","author":"Wang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025825118","article-title":"Hierarchy of Signaling Thresholds Downstream of the T Cell Receptor and the Tec Kinase ITK","volume":"118","author":"Gallagher","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.06.023","article-title":"SH2-Dependent Autophosphorylation Within the Tec Family Kinase Itk","volume":"391","author":"Joseph","year":"2009","journal-title":"J Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716405","article-title":"The Tec Kinase Itk Integrates Na\u00efve T Cell Migration and In Vivo Homeostasis","volume":"12","author":"Thelen","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/297868","article-title":"Itk: The Rheostat of the T Cell Response","volume":"2011","author":"Grasis","year":"2011","journal-title":"J Signal Transd"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14304\/surya.jpr.v2n6.1","article-title":"Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) in T-Cell Related Diseases","volume":"2","author":"Zhong","year":"2014","journal-title":"Postdoc J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","article-title":"Combining BTK Inhibitors With BCL2 Inhibitors for Treating Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma","volume":"10","author":"Zhang","year":"2022","journal-title":"biomark Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib Modulates the Immunosuppressive CLL Microenvironment Through STAT3-Mediated Suppression of Regulatory B-Cell Function and Inhibition of the PD-1\/PD-L1 Pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic Antitumor Immunity by Checkpoint Blockade is Enhanced by Ibrutinib, an Inhibitor of Both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining Ibrutinib and Checkpoint Blockade Improves CD8+ T-Cell Function and Control of Chronic Lymphocytic Leukemia in Em-TCL1 Mice","volume":"106","author":"Hanna","year":"2021","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400968","article-title":"IL-2-Inducible T Cell Kinase Tunes T Regulatory Cell Development and is Required for Suppressive Function","volume":"193","author":"Huang","year":"2014","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131459","article-title":"Itk-Mediated Integration of T Cell Receptor and Cytokine Signaling Regulates the Balance Between Th17 and Regulatory T Cells","volume":"211","author":"Gomez-Rodriguez","year":"2014","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.625","article-title":"Interleukin-2-Inducible T-Cell Kinase (Itk) Signaling Regulates Potent Noncanonical Regulatory T Cells","volume":"11","author":"Mammadli","year":"2021","journal-title":"Clin Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023235","article-title":"Differential Inhibitor Sensitivity Between Human Kinases VRK1 and VRK2","volume":"6","author":"Vazquez-Cedeira","year":"2011","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310813200","article-title":"Characterization of Three Paralogous Members of the Mammalian Vaccinia Related Kinase Family","volume":"279","author":"Nichols","year":"2004","journal-title":"J Biol Chem"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.404285","article-title":"Human VRK2 (Vaccinia-Related Kinase 2) Modulates Tumor Cell Invasion by Hyperactivation of NFAT1 and Expression of Cyclooxygenase-2","volume":"287","author":"Vazquez-Cedeira","year":"2012","journal-title":"J Biol Chem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2006.05256.x","article-title":"The Subcellular Localization of Vaccinia-Related Kinase-2 (VRK2) Isoforms Determines Their Different Effect on P53 Stability in Tumour Cell Lines","volume":"273","author":"Blanco","year":"2006","journal-title":"FEBS J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001660","article-title":"Modulation of Interleukin-1 Transcriptional Response by the Interaction Between VRK2 and the JIP1 Scaffold Protein","volume":"3","author":"Blanco","year":"2008","journal-title":"PloS One"},{"key":"B63","unstructured":"VRK2 The Human Protein Atlas"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2005.11.582","article-title":"COX-2 Induces IL-11 Production in Human Breast Cancer Cells","volume":"131","author":"Singh","year":"2006","journal-title":"J Surg Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01893-4","article-title":"Vaccinia-Related Kinase 2 Drives Pancreatic Cancer Progression by Protecting Plk1 From Chfr-Mediated Degradation","volume":"40","author":"Zhu","year":"2021","journal-title":"Oncogene"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.28.474386","article-title":"VRK1 is Required in VRK2-Methylated Cancers of the Nervous System","author":"So","year":"2021","journal-title":"bioRxiv"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1521-3","article-title":"COX2 Overexpression Is a Prognostic Marker for Stage III Breast Cancer","volume":"132","author":"Kim","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600184200","article-title":"NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2","volume":"281","author":"Yiu","year":"2006","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.40","article-title":"Human VRK2 Modulates Apoptosis by Interaction With Bcl-xL and Regulation of BAX Gene Expression","volume":"4","author":"Monsalve","year":"2013","journal-title":"Cell Death Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01581-09","article-title":"VRK2 Inhibits Mitogen-Activated Protein Kinase Signaling and Inversely Correlates With ErbB2 in Human Breast Cancer","volume":"30","author":"Fernandez","year":"2010","journal-title":"Mol Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2021.03.007","article-title":"VRK2 Inhibition Synergizes With PD-1 Blockade to Improve T Cell Responses","volume":"233","author":"Peled","year":"2021","journal-title":"Immunol Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00082","article-title":"Development of Pyridine-Based Inhibitors for the Human Vaccinia-Related Kinases 1 and 2","volume":"10","author":"Serafim","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807917","article-title":"Shared and Distinct Genetic Variants in Type 1 Diabetes and Celiac Disease","volume":"359","author":"Smyth","year":"2008","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-018-1187-4","article-title":"Molecular and Clinical Characterization of PTPN2 Expression From RNA-Seq Data of 996 Brain Gliomas","volume":"15","author":"Wang","year":"2018","journal-title":"J Neuroinflammation"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29227","article-title":"PTPN2 Induced by Inflammatory Response and Oxidative Stress Contributed to Glioma Progression","volume":"120","author":"Wu","year":"2019","journal-title":"J Cell Biochem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_21012","article-title":"Inflammatory Response or Oxidative Stress Induces Upregulation of PTPN2 and Thus Promotes the Progression of Laryngocarcinoma","volume":"24","author":"Yang","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.11.047","article-title":"Upregulated PTPN2 Induced by Inflammatory Response or Oxidative Stress Stimulates the Progression of Thyroid Cancer","volume":"522","author":"Zhang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2018.1465013","article-title":"PTPN2 as a Promoter of Colon Carcinoma via Reduction of Inflammasome Activation","volume":"5","author":"Spalinger","year":"2018","journal-title":"Mol Cell Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.01.052","article-title":"PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer","volume":"22","author":"Spalinger","year":"2018","journal-title":"Cell Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/ng.587","article-title":"Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia","volume":"42","author":"Kleppe","year":"2010","journal-title":"Nat Genet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314286","article-title":"PTPN2 Negatively Regulates Oncogenic JAK1 in T-Cell Acute Lymphoblastic Leukemia","volume":"117","author":"Kleppe","year":"2011","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.5.683","article-title":"Impaired Bone Marrow Microenvironment and Immune Function in T Cell Protein Tyrosine Phosphatase-Deficient Mice","volume":"186","author":"You-Ten","year":"1997","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161903","article-title":"PTPN2 Regulates T Cell Lineage Commitment and \u03b1\u03b2 Versus \u03b3\u03b4 Specification","volume":"214","author":"Wiede","year":"2017","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.608747","article-title":"Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy","volume":"8","author":"Castro-Sanchez","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107957","article-title":"PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells","volume":"32","author":"Flosbach","year":"2020","journal-title":"Cell Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.05.008","article-title":"PTPN2 Restrains CD8+ T Cell Responses After Antigen Cross-Presentation for the Maintenance of Peripheral Tolerance in Mice","volume":"53","author":"Wiede","year":"2014","journal-title":"J Autoimmun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.122","article-title":"PTPN2 Controls Differentiation of CD4+ T Cells and Limits Intestinal Inflammation and Intestinal Dysbiosis","volume":"8","author":"Spalinger","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0480-4","article-title":"PTPN2 Regulates the Generation of Exhausted CD8+ T Cell Subpopulations and Restrains Tumor Immunity","volume":"20","author":"LaFleur","year":"2019","journal-title":"Nat Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nature23270","article-title":"In Vivo CRISPR Screening Identifies Ptpn2 as a Cancer Immunotherapy Target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1438106","article-title":"Melanoma Response to Anti-PD-L1 Immunotherapy Requires JAK1 Signaling, But Not JAK2","volume":"7","author":"Luo","year":"2018","journal-title":"OncoImmunology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121233","article-title":"Synergistic Photothermal Cancer Immunotherapy by Cas9 Ribonucleoprotein-Based Copper Sulfide Nanotherapeutic Platform Targeting PTPN2","volume":"279","author":"Yan","year":"2021","journal-title":"Biomaterials"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061427","article-title":"The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment","volume":"9","author":"Augello","year":"2020","journal-title":"Cells"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/biology10070610","article-title":"GSK-3\u03b2 in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties","volume":"10","author":"Park","year":"2021","journal-title":"Biol (Basel)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102555","article-title":"Non-Redundant Activity of GSK-3alpha and GSK-3beta in T Cell-Mediated Tumor Rejection","volume":"24","author":"Steele","year":"2021","journal-title":"iScience"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen Synthase Kinase-3 (GSK3): Regulation, Actions, and Diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061388","article-title":"Glycogen Synthase Kinase 3\u03b2 in Cancer Biology and Treatment","volume":"9","author":"Domoto","year":"2020","journal-title":"Cells"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/35096075","article-title":"The Renaissance of GSK3","volume":"2","author":"Cohen","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","article-title":"Glycogen Synthase Kinase-3 From Rabbit Skeletal Muscle","volume":"107","author":"Embi","year":"1980","journal-title":"Eur J Biochem"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621050","article-title":"Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancer-A Clinicopathological Series","volume":"11","author":"Alves","year":"2021","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091231","article-title":"Gsk3\u03b2 Overexpression Indicates Poor Prognosis and its Inhibition Reduces Cell Proliferation and Survival of non-Small Cell Lung Cancer Cells","volume":"9","author":"Zeng","year":"2014","journal-title":"PloS One"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.018","article-title":"Glycogen Synthase Kinase 3 Inactivation Drives T-Bet-Mediated Downregulation of Co-Receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses","volume":"44","author":"Taylor","year":"2016","journal-title":"Immunity"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1412900","article-title":"Modulation of CD8+ Memory Stem T Cell Activity and Glycogen Synthase Kinase 3\u03b2 Inhibition Enhances Anti-Tumoral Immunity in Gastric Cancer","volume":"7","author":"Zhang","year":"2018","journal-title":"OncoImmunology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-0491","article-title":"Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy","volume":"78","author":"Taylor","year":"2018","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120635","article-title":"Immune Checkpoint Inhibition in Syngeneic Mouse Cancer Models by a Silicasome Nanocarrier Delivering a GSK3 Inhibitor","volume":"269","author":"Allen","year":"2021","journal-title":"Biomaterials"},{"key":"B105","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.192.1.99","article-title":"Negative Regulation of T Cell Proliferation and Interleukin 2 Production by the Serine Threonine Kinase Gsk-3","volume":"192","author":"Ohteki","year":"2000","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01221","article-title":"The Role of GSK3beta in T Lymphocytes in the Tumor Microenvironment","volume":"10","author":"Dimou","year":"2020","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.6.2729","article-title":"CD28 Costimulation Mediates Down-Regulation of P27kip1 and Cell Cycle Progression by Activation of the PI3K\/PKB Signaling Pathway in Primary Human T Cells","volume":"168","author":"Appleman","year":"2002","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01653","article-title":"Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8(+) Cytotoxic T-Cells: Implications for Anti-PD-1 Immunotherapy","volume":"8","author":"Taylor","year":"2017","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1982","article-title":"Wnt Signaling Arrests Effector T Cell Differentiation and Generates CD8+ Memory Stem Cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101295","article-title":"Glycogen Synthase 3 (GSK-3) Regulation of PD-1 Expression and and its Therapeutic Implications","volume":"42","author":"Krueger","year":"2019","journal-title":"Semin Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-021-01420-9","article-title":"AMPK Promotes Antitumor Immunity by Downregulating PD-1 in Regulatory T Cells via the HMGCR\/p38 Signaling Pathway","volume":"20","author":"Pokhrel","year":"2021","journal-title":"Mol Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.celrep.2020.01.076","article-title":"Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-Receptor LAG-3 for Enhanced Anti-Tumor Immunity","volume":"30","author":"Rudd","year":"2020","journal-title":"Cell Rep"},{"key":"B113","doi-asserted-by":"crossref","first-page":"165.35","DOI":"10.4049\/jimmunol.204.Supp.165.35","article-title":"CD28 and Glycogen Synthase Kinase-3 (GSK-3) Inhibitor Combination Therapy Generates Tumor Infiltrating T-Cells (TILs) With a Reversal of Markers for T-Cell Exhaustion","volume":"204","author":"Kazanova","year":"2020","journal-title":"J Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.06.035","article-title":"Glycogen Synthase Kinase 3 Inhibition Lowers PD-1 Expression, Promotes Long-Term Survival and Memory Generation in Antigen-Specific CAR-T Cells","volume":"433","author":"Sengupta","year":"2018","journal-title":"Cancer Lett"},{"key":"B115","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13104-020-04971-0","article-title":"Glycogen Synthase Kinase 3 (GSK-3) Controls T-Cell Motility and Interactions With Antigen Presenting Cells","volume":"13","author":"Taylor","year":"2020","journal-title":"BMC Res Notes"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and Stabilization of Programmed Death Ligand-1 Suppresses T-Cell Activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004026","article-title":"Eef2k Promotes PD-L1 Stabilization Through Inactivating GSK3\u03b2 in Melanoma","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B118","article-title":"Disulfiram Combined With Copper Induces Immunosuppression via PD-L1 Stabilization in Hepatocellular Carcinoma","volume":"9","author":"Zhou","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B119","doi-asserted-by":"crossref","first-page":"136.24","DOI":"10.4049\/jimmunol.202.Supp.136.24","article-title":"Glycogen Synthase Kinase 3 (GSK-3) Synergizes With Immune-Checkpoint Blockade (ICB) to Overcome Tumor Resistance Due to Unique Tumor Infiltrating T-Cell Subsets as Revealed by Mass Cytometry (CyTOF)","volume":"202","author":"Krueger","year":"2019","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-Derived CD19-Targeted T Cells Cause Regression of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0799","article-title":"GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity","volume":"77","author":"Cichocki","year":"2017","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression Patterns of NKG2A, KIR, and CD57 Define a Process of CD56dim NK-Cell Differentiation Uncoupled From NK-Cell Education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11154","article-title":"Repression of GSK3 Restores NK Cell Cytotoxicity in AML Patients","volume":"7","author":"Parameswaran","year":"2016","journal-title":"Nat Commun"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK Inhibitors: Positive and Negative Regulators of G1-Phase Progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.01206-14","article-title":"Brk\/Protein Tyrosine Kinase 6 Phosphorylates P27kip1, Regulating the Activity of Cyclin D-Cyclin-Dependent Kinase 4","volume":"35","author":"Patel","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 Kinases: From Basic Science to Cancer Therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.10.001","article-title":"A Systematic Screen for CDK4\/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells","volume":"20","author":"Anders","year":"2011","journal-title":"Cancer Cell"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/nature02650","article-title":"Cyclin-Dependent Kinases Regulate the Antiproliferative Function of Smads","volume":"430","author":"Matsuura","year":"2004","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.Cd-14-0625","article-title":"PRMT5 is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discovery"},{"key":"B131","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0065-230x(08)60352-8","article-title":"Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer","volume":"68","author":"Hall","year":"1996","journal-title":"Adv Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.05.064","article-title":"Cyclin D1 in Breast Cancer Pathogenesis","volume":"23","author":"Arnold","year":"2005","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/369669a0","article-title":"Mammary Hyperplasia and Carcinoma in MMTV-Cyclin D1 Transgenic Mice","volume":"369","author":"Wang","year":"1994","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2005.12.019","article-title":"Cyclin D1-Dependent Kinase Activity in Murine Development and Mammary Tumorigenesis","volume":"9","author":"Landis","year":"2006","journal-title":"Cancer Cell"},{"key":"B135","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ccr.2010.05.025","article-title":"A Synthetic Lethal Interaction Between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-Small Cell Lung Carcinoma","volume":"18","author":"Puyol","year":"2010","journal-title":"Cancer Cell"},{"key":"B136","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell Cycle Proteins as Promising Targets in Cancer Therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1212","article-title":"ATP-Competitive Inhibitors Block Protein Kinase Recruitment to the Hsp90-Cdc37 System","volume":"9","author":"Polier","year":"2013","journal-title":"Nat Chem Biol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-4559","article-title":"Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts","volume":"70","author":"Michaud","year":"2010","journal-title":"Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062745","article-title":"Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination With Temozolomide in an Intracranial Glioblastoma Xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 Inhibition Triggers Anti-Tumour Immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-0915","article-title":"CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-Cell Activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discovery"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 Kinase Destabilizes PD-L1 via Cullin 3-SPOP to Control Cancer Immune Surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"B144","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-2210","article-title":"Combined CDK4\/6 and PI3K\u03b1 Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer","volume":"77","author":"Teo","year":"2017","journal-title":"Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-15-0775","article-title":"Preclinical Characterization of G1T28: A Novel CDK4\/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 Inhibition Protects Hematopoietic Stem Cells From Chemotherapy-Induced Exhaustion","volume":"9","author":"He","year":"2017","journal-title":"Sci Transl Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.9.1591","article-title":"Phosphoprotein Associated With Glycosphingolipid-Enriched Microdomains (PAG), a Novel Ubiquitously Expressed Transmembrane Adaptor Protein, Binds the Protein Tyrosine Kinase Csk and is Involved in Regulation of T Cell Activation","volume":"191","author":"Brdicka","year":"2000","journal-title":"J Exp Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2008.06.006","article-title":"Phosphoprotein Associated With Glycosphingolipid-Enriched Microdomains\/Csk-Binding Protein: A Protein That Matters","volume":"204","author":"Svec","year":"2008","journal-title":"Pathol Res Pract"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.485","article-title":"PAG - A Multipurpose Transmembrane Adaptor Protein","volume":"33","author":"Hrdinka","year":"2014","journal-title":"Oncogene"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.3.1251","article-title":"Non-CD28 Costimulatory Molecules Present in T Cell Rafts Induce T Cell Costimulation by Enhancing the Association of TCR With Rafts","volume":"164","author":"Yashiro-Ohtani","year":"2000","journal-title":"J Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2013.07.018","article-title":"Interaction of Membrane\/Lipid Rafts With the Cytoskeleton: Impact on Signaling and Function: Membrane\/Lipid Rafts, Mediators of Cytoskeletal Arrangement and Cell Signaling","volume":"1838","author":"Head","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02225-8","article-title":"Transmembrane Adaptor Protein PAG is a Mediator of PD-1 Inhibitory Signaling in Human T Cells","volume":"4","author":"Strazza","year":"2021","journal-title":"Commun Biol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2003.10.013","article-title":"Transmembrane Adaptor Proteins in Membrane Microdomains: Important Regulators of Immunoreceptor Signaling","volume":"92","author":"Horejsi","year":"2004","journal-title":"Immunol Lett"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.2.541","article-title":"Cutting Edge: Negative Regulation of Immune Synapse Formation by Anchoring Lipid Raft to Cytoskeleton Through Cbp-EBP50-ERM Assembly","volume":"168","author":"Itoh","year":"2002","journal-title":"J Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(01)02955-6","article-title":"Interaction Between Two Adapter Proteins, PAG and EBP50: A Possible Link Between Membrane Rafts and Actin Cytoskeleton","volume":"507","author":"Brdickov\u00e1","year":"2001","journal-title":"FEBS Lett"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-8-8","article-title":"PDZ Domains and Their Binding Partners: Structure, Specificity, and Modification","volume":"8","author":"Lee","year":"2010","journal-title":"Cell Commun Signaling"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5649790","article-title":"The Scribble Complex PDZ Proteins in Immune Cell Polarities","volume":"2020","author":"Barreda","year":"2020","journal-title":"J Immunol Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.591348","article-title":"Coordinating Cytoskeleton and Molecular Traffic in T Cell Migration, Activation, and Effector Functions","volume":"8","author":"Mastrogiovanni","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.651703","article-title":"Protein-Tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase","volume":"290","author":"Fan","year":"2015","journal-title":"J Biol Chem"},{"key":"B161","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s1074-7613(00)80315-5","article-title":"Complex Complexes: Signaling at the TCR","volume":"5","author":"Wange","year":"1996","journal-title":"Immunity"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093470","article-title":"Roles of Raft-Anchored Adaptor Cbp\/PAG1 in Spatial Regulation of C-Src Kinase","volume":"9","author":"Saitou","year":"2014","journal-title":"PloS One"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E20-02-0135","article-title":"PAG1 Directs SRC-Family Kinase Intracellular Localization to Mediate Receptor Tyrosine Kinase-Induced Differentiation","volume":"31","author":"Foltz","year":"2020","journal-title":"Mol Biol Cell"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.6.2017-2028.2003","article-title":"Phosphorylation-Dependent Regulation of T-Cell Activation by PAG\/Cbp, a Lipid Raft-Associated Transmembrane Adaptor","volume":"23","author":"Davidson","year":"2003","journal-title":"Mol Cell Biol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.11.035","article-title":"The Csk-Associated Adaptor PAG Inhibits Effector T Cell Activation in Cooperation With Phosphatase PTPN22 and Dok Adaptors","volume":"17","author":"Davidson","year":"2016","journal-title":"Cell Rep"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.10.118","article-title":"Upregulation of PAG1\/Cbp Contributes to Adipose-Derived Mesenchymal Stem Cells Promoted Tumor Progression and Chemoresistance in Breast Cancer","volume":"494","author":"Lu","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26885","article-title":"Identification of Integrin \u03b21 as a Novel PAG1-Interacting Protein Involved in the Inherent Radioresistance of Human Laryngeal Carcinoma","volume":"9","author":"Dong","year":"2018","journal-title":"J Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2018.06.014","article-title":"PAG1 Promotes the Inherent Radioresistance of Laryngeal Cancer Cells via Activation of STAT3","volume":"370","author":"Shen","year":"2018","journal-title":"Exp Cell Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2021.100911","article-title":"Influence of Pentoxifylline on Gene Expression of PAG1\/miR-1206\/SNHG14 in Ischemic Heart Disease","volume":"25","author":"Abd el-Aziz","year":"2021","journal-title":"Biochem Biophysics Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.927265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T15:34:00Z","timestamp":1676129640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.927265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":169,"alternative-id":["10.3389\/fimmu.2022.927265"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.927265","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"927265"}}